About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

SAR425899

Company: Sanofi
Mechanism: Mechanism not yet reported
Route: Route not yet reported
Recruiting trials: None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Trial details

Completed NCT NCT02411825

Multiple Ascending Dose Study in Healthy Male Subjects and Overweight to Obese Male and Female Type 2 Diabetes Mellitus (T2DM) Patients

Not yet reported Sanofi 76 participants Est. completion 2016-01 1 site Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT02973321

A Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes Mellitus

Not yet reported Sanofi 296 participants Est. completion 2017-12-27 59 sites Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT03350191

A Clinical Study to Investigate if SAR425899 Binds to the Liver and Pancreas in Overweight to Obese Type 2 Diabetes Mellitus Patients

Not yet reported Sanofi 13 participants Est. completion 2018-06-07 1 site Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT03376802

A Clinical Study to Investigate the Effect of SAR425899 on Energy Expenditure in Obese Subjects

Not yet reported Sanofi 24 participants Est. completion 2018-12-27 2 sites Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT03414736

A Study on Safety and Tolerability of SAR425899 in Overweight to Obese Subjects and Type 2 Diabetes Mellitus Patients Not Requiring Anti-Diabetic Pharmacotherapy With an Optional 6-month Safety Extension Period

Not yet reported Sanofi 60 participants Est. completion 2018-10-05 3 sites Stand-alone

Type 2 diabetes
View official trial listing →
Withdrawn NCT NCT03437720

Assessment of the Safety and Effect of SAR425899 Versus Placebo for the Treatment of Non-alcoholic Fatty Liver Disease

Not yet reported Sanofi Est. completion 2021-08-25 Stand-alone

Type 2 diabetes Other conditions: Non-alcoholic Steatohepatitis
View official trial listing →

Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

ClinicalTrials.gov — NCT03350191

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.